Hepg2

Manufactured by GE Healthcare

Sourced in Sweden, United States, China, Austria

HepG2 is a human liver cancer cell line commonly used in laboratory research. It is a well-established and widely-used model system for studying various aspects of liver biology and function, including drug metabolism, toxicity, and signaling pathways.

Automatically generated - may contain errors

Lab products found in correlation

Huh 7, by GE Healthcare (3 mentions) Dulbecco modified eagle medium (dmem), by GE Healthcare (2 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) Protein a bead, by Thermo Fisher Scientific (1 mentions) Hepg2, by Thermo Fisher Scientific (1 mentions) Protease inhibitor cocktail, by Roche (1 mentions) Fetal bovine serum (fbs), by GE Healthcare (1 mentions) B1760, by Merck Group (1 mentions) Dmem high glucose medium, by GE Healthcare (1 mentions) Hep3b, by GE Healthcare (1 mentions) Fugene transfection reagent, by Promega (1 mentions) Iscove modified dulbecco media (imdm), by GE Healthcare (1 mentions) Hepg2, by American Type Culture Collection (1 mentions) Interferin sirna transfection reagent, by Polyplus Transfection (1 mentions) Rpmi 1640, by GE Healthcare (1 mentions)

Close spelling variants of this product

HepG2 cells

5 protocols using hepg2

Liver Cancer Cell Line Transfection

Check if the same lab product or an alternative is used in the 5 most similar protocols

The liver cancer cell lines, HepG2 and Huh-7, were purchased from the American Type Culture Collection (ATCC). The cell lines were authenticated by STR profiling. The cells were maintained in a humidified incubator under standard conditions (37°C, 5% CO₂) in IMDM (PAA Laboratories supplemented with 10% fetal calf serum (FCS).
For siRNA transfection, 5×10² (HepG2) or 3×10² (Huh-7) cells/well were seeded in a 96-well plate, or 3×10⁵ (HepG2) or 2×10⁵ (Huh-7) cells in a 24-well plate, respectively, and incubated under standard conditions unless stated otherwise. Using the INTERFERin™ siRNA transfection reagent (Polyplus), 2.5 nM siRNA (for sequences, see Table SI) for proliferation assays or 5 nM siRNA for all other assays were transfected according to the manufacturer’s instructions and incubated for the time periods as indicated in the figures. The cells were then analyzed in the well plates or harvested by trypsinization and subsequent transfer to Eppendorf cups and used as described below.
Transfection of 400 ng plasmid DNA per 24 well was performed using FuGENE^® transfection reagent (Promega) according to the manufacturer’s protocol and incubated at 37°C for 6 h, prior to media change and siRNA transfection.

Kronschnabl P., Grünweller A., Hartmann R.K., Aigner A, & Weirauch U. (2019). Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression. International Journal of Oncology, 56(2), 448-459.

+ Open protocol

+ Expand

LXRα and Smad3 Interaction Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

293-T (3 × 10⁵ per 6-well) and HepG2 (4 × 10⁵ per 60-mm dish) cells were transfected with pCMX-LXRα and/or pCDNA3-Flag-Smad3 plasmids (200 ng) for 48 h, using calcium phosphate (293-T) or lipofectamine-3000 (HepG2; Life Technologies, Stockholm, Sweden). Intact or transfected cells were lysed in 20 mM Tris, pH 7.5, 100 mM NaCl, 0.5% NP-40, 0.5 mM EDTA and protease inhibitor cocktail (Roche Diagnostics, Bromma, Sweden). Lysates were pre-cleared with protein-A beads (ThermoFisher Scientific, Fyrislund, Sweden), incubated with 0.9 μg biotinylated DNA probe (Eurofins, Uppsala, Sweden) and 15 μg salmon sperm DNA (in-house) for 90 min (293-T) or 3 h (HepG2), and with magnetic streptavidin-sepharose beads (GE Healthcare, Uppsala, Sweden) for 45 min; three washes were performed with lysis buffer prior to sequential immunoblot analysis on the same membrane using LXRα and Smad3 antibodies (see immunoblotting). The biotinylated double-stranded hACTA2 promoter probe sequence was: 5’-CAAGGAGGTTAGTGGGCAGAGAGGAGGGCTACAGAGGC-3’. Quadruplicate (n_b = 4) biological experiments were performed in 2 technical replicates (n_t = 2) per condition.

Morén A., Bellomo C., Tsubakihara Y., Kardassis D., Mikulits W., Heldin C.H, & Moustakas A. (2019). LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation. Oncogenesis, 8(6), 36.

+ Open protocol

+ Expand

Hep-G2 Cell Exposure to Benzo(a)Pyrene

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human hepatoblastoma Hep-G2 cell line was purchased from the Cell Resource Center, Peking Union Medical College (National Infrastructure of Cell Line Resource, Beijing, China). Hep-G2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) supplemented with 10% fetal bovine serum (FBS) (GE Healthcare Bio-Sciences) and antibiotics (penicillin 100 U/ml and streptomycin 100 µg/ml) in an incubator with a humidified atmosphere of 5% CO₂ at 37°C. For BaP exposure, Hep-G2 cells were treated with different concentrations (0, 2, 4, 8, 16, 32 or 64 µM) of BaP (B1760; >96% HPLC; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at different time points (0, 24, 48 or 72 h), as described previously (29 (link),30 (link)). The final concentration of dimethyl sulfoxide (DMSO) used as solvent control was 0.1% (v/v) or less.

Wang Y., Pan T., Li L., Wang H., Zhang D, & Yang H. (2018). Benzo(a)pyrene promotes Hep-G2 cell migration and invasion by upregulating phosphorylated extracellular signal-regulated kinase expression. Oncology Letters, 15(6), 8325-8332.

+ Open protocol

+ Expand

Curative Surgical Resection of HCC

Check if the same lab product or an alternative is used in the 5 most similar protocols

The paired HCC samples and the adjacent non-tumor tissues were collected following curative surgical resection from 48 patients with HCC in the Zhongnan Hospital of Wuhan University between May 2011 and May 2013. This study was approved by the Hospital's Protection of Human Subjects Committee, and written informed consent was obtained from all patients. Based on their medical documents, we conducted a 48-month follow-up survival survey. Overall survival (OS) was defined as the interval between resection and death or the last follow-up visit. Curative resection was defined as the removal of all recognizable tumor tissue with a clear microscopic margin. HepG2, Hep3B, Huh-7, HCCLM9, SK-Hep1, and SMMC-7721 cell lines included in this study were purchased from the Cell Bank of Type Culture Collection (CBTCC, Chinese Academy of Sciences, Shanghai, China) and cultured in Dulbecco's Modified Eagle's Medium (DMEM)/ high-glucose medium (GE Healthcare Life Sciences HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin and streptomycin in a humidified atmosphere of 5% CO 2 at 37°C.

Lan T., Yan X., Li Z., Xu X., Mao Q., Ma W., Hong Z., Chen X, & Yuan Y. (2017). Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 39(6).

+ Open protocol

+ Expand

Cellular Expression of Nuclear Receptors

Check if the same lab product or an alternative is used in the 5 most similar protocols

All cell lines were obtained from the Cell Bank of the Chinese Academy of Science (Shanghai, China). HEK293, Huh7 cell line and normal human hepatic cell line L-02 were maintained in RPMI1640 with 10% FBS (PAA Laboratories, Pasching, Austria). Human HCC cell lines HepG2, Hep3B, SMMC-7721, Huh7 and normal human hepatic cell line Chang were maintained in DMEM with 10% FBS (PAA Laboratories, Pasching, Austria). Antibodies specific to estrogen-related receptor gamma and β-actin were obtained from Sigma (Beijing, China).

Yuan B., Liang Y., Wang D, & Luo F. (2015). MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients. Cancer Science, 106(7), 819-824.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!